Its complete income from operations stood at Rs 8,382 crore for the fourth quarter in comparison with Rs 7,580 crore within the year-ago interval, Aurobindo Pharma mentioned in a regulatory submitting.
For the total 12 months ended March 31, 2025, the corporate mentioned its PAT rose 10 per cent to Rs 3,484 crore in opposition to Rs 3,169 crore in FY24.
The full income from operations rose to Rs 31,724 crore final fiscal from Rs 29,002 crore in 2023-24.
“We’re happy to ship one other quarter and 12 months of all-time excessive gross sales and EBITDA, reflecting the power of our core companies, constant volume-led progress, and the depth of our differentiated product portfolio,” Aurobindo Pharma Vice-Chairman and MD Ok Nithyananda Reddy mentioned.
The drug agency’s European operations proceed to carry out exceptionally nicely, transferring steadily in the direction of the USD 1 billion income milestone, he added. “Backed by our ongoing capability enhancements we stay firmly positioned to maintain our trajectory and create long-term worth for our stakeholders,” Reddy mentioned.
Aurobindo Pharma shares on Monday ended 1.43 per cent down at Rs 1,179.35 apiece on BSE.
